The long-chain polyfluorinated alkyl substance perfluorohexane sulfonate (PFHxS) promotes bone marrow adipogenesis.

Toxicol Appl Pharmacol

Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, United States of America; Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, MI, United States of America. Electronic address:

Published: October 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Per- and polyfluoroalkyl substances (PFAS) bioaccumulate in different organ systems, including bone. While existing research highlights the adverse impact of PFAS on bone density, a critical gap remains in understanding the specific effects on the bone marrow microenvironment, especially the bone marrow adipose tissue (BMAT). Changes in BMAT have been linked to various health consequences, such as the development of osteoporosis and the progression of metastatic tumors in bone. Studies presented herein demonstrate that exposure to a mixture of five environmentally relevant PFAS compounds promotes marrow adipogenesis in vitro and in vivo. We show that among the components of the mixture, PFHxS, an alternative to PFOS, has the highest propensity to accumulate in bone and effectively promote marrow adipogenesis. Utilizing RNAseq approaches, we identified the peroxisome proliferator-activated receptor (PPAR) signaling as a top pathway modulated by PFHxS exposure. Furthermore, we provide results suggesting the activation and involvement of PPAR-gamma (PPARγ) in PFHxS-mediated bone marrow adipogenesis, especially in combination with high-fat diet. In conclusion, our findings demonstrate the potential impact of elevated PFHxS levels, particularly in occupational settings, on bone health, and specifically bone marrow adiposity. This study contributes new insights into the health risks of PFHxS exposure, urging further research on the relationship between environmental factors, diet, and adipose tissue dynamics.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12247039PMC
http://dx.doi.org/10.1016/j.taap.2024.117047DOI Listing

Publication Analysis

Top Keywords

bone marrow
20
marrow adipogenesis
16
bone
10
adipose tissue
8
pfhxs exposure
8
marrow
7
pfhxs
5
long-chain polyfluorinated
4
polyfluorinated alkyl
4
alkyl substance
4

Similar Publications

Langerhans cell sarcoma (LCS) is an aggressive malignant neoplasm with a Langerhans cell immunophenotype and high-grade cytological features. Occasionally, it can coexist with other hematopoietic neoplasms with proven clonal relationship. Most of these neoplasms were found to be of lymphoid origin.

View Article and Find Full Text PDF

Adoptive cellular therapies in multiple myeloma.

Best Pract Res Clin Haematol

September 2025

Department of Personalized Medicine and Rare Diseases, Medfuture Institute for Biomedical Research - Department of Hematology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Hematology, Ion Chiricuta Cancer Center, Cluj Napoca, Romania. Electronic address:

Plasma cell myeloma (multiple myeloma) is a blood cancer characterized by the clonal proliferation of plasma cells in the bone marrow. Treatment strategies evolve year by year, new drugs getting Food and Drug Administration (FDA)-approved each year. Chimeric antigen receptor (CAR) therapies are an advanced form of immunotherapy that engineer T cells to recognize and destroy cancer cells.

View Article and Find Full Text PDF

Adoptive cellular therapies in non-Hodgkin lymphomas.

Best Pract Res Clin Haematol

September 2025

Department of Personalized Medicine and Rare Diseases, Medfuture Institute for Biomedical Research - Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Hematology, Ion Chiricuta Cancer Center, Cluj Napoca, Romania. Electronic address: c

Lymphomas are a group of malignant proliferations of B, T or NK-lymphoid cells at different stages of maturation. While they primarily occur in lymph nodes or lymphatic tissues, they can also involve bone marrow, blood, or other organs. Despite advances in treatment, many patients experience relapse, or develop refractory disease, prompting the development of new therapies.

View Article and Find Full Text PDF

The Optimal Adjuvant Reinfusion Strategy for Aplastic Anemia: Umbilical Cord Blood or Mesenchymal Stem Cells? A Single-Center Retrospective Study.

Transplant Cell Ther

September 2025

Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine); Hangzhou, China; The First School of Clinical Medicine, Zhejiang Chinese Medical University; Hangzhou, China. Electronic address: szyyblood@1

Aplastic anemia (AA) is a bone marrow failure disorder treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Despite improvements in conditioning regimens and GVHD prophylaxis, graft failure and GVHD remain critical challenges. This study compared the efficacy of mesenchymal stem cells (MSCs) and umbilical cord blood cells (UCBs) as adjunctive therapies in 184 AA patients undergoing allo-HSCT.

View Article and Find Full Text PDF

GLP-1R activation restores Gas6-driven efferocytosis in senescent foamy macrophages to promote neural repair.

Redox Biol

September 2025

Department of Spine Surgery, The Second Affiliated Hospital of Nantong University, Nantong First People's Hospital, Medical School of Nantong University, Nantong, Jiangsu, 226000, China; Research Institute for Spine and Spinal Cord Disease of Nantong University, Nantong, Jiangsu, 226000, China. Elec

Spinal cord injury (SCI) is a devastating condition characterized by the accumulation of myelin debris (MD), persistent neuroinflammation, and impaired neural regeneration. Although macrophages are pivotal for MD clearance, the impact of excessive MD phagocytosis on macrophage phenotype and function remains poorly understood. Building upon our prior evidence that exendin-4 (Ex-4), a glucagon-like peptide-1 receptor (GLP-1R) agonist, mitigates microglia-driven neuroinflammation post-SCI, this study elucidates the therapeutic efficacy and underlying mechanisms of Ex-4 in alleviating macrophage senescence, restoring efferocytotic capacity, and facilitating neural repair.

View Article and Find Full Text PDF